Description:
The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema. SMVL is defined as a 15 letter or more decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity that is sustained for the patient's last 6 months of study participation. The SMVL data from this study will be combined with the SMVL data from Study B7A-MC-MBDL for the purpose of comparing ruboxistaurin to placebo.
Keywords:
Versions (1) ▾
- 12/9/13
Uploaded on:
December 9, 2013
DOI:
No DOI assigned. To request one pleaselog in.License:
Creative Commons BY-NC 3.0 LegacyModel comments:
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for:
Item comments for:
In order to download data models you must be logged in. Please log in or register for free.